Cargando…
Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers betwee...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Gynecologic Oncology and Colposcopy
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325355/ https://www.ncbi.nlm.nih.gov/pubmed/22523624 http://dx.doi.org/10.3802/jgo.2012.23.2.91 |
_version_ | 1782229428225441792 |
---|---|
author | Kim, Myung Joo Jung, Yong Wook Seong, Seok Ju Yoon, Bo Sung Kim, Mi La Joo, Won Deok Song, Tae Jong |
author_facet | Kim, Myung Joo Jung, Yong Wook Seong, Seok Ju Yoon, Bo Sung Kim, Mi La Joo, Won Deok Song, Tae Jong |
author_sort | Kim, Myung Joo |
collection | PubMed |
description | OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers between April 2008 and February 2011. Cisplatin (70 mg/m(2) in 1 L normal saline solution) was administered in the abdominal cavity for 24 hours postoperatively and then adjuvant chemotherapy was started 2-4 weeks after surgery. Perioperative toxicity of the combined treatment was evaluated until the initiation of postoperative adjuvant chemotherapy. RESULTS: A total of 23 adverse events were observed in 9 of 10 patients (grade 1, 7; grade 2, 13; grade 3, 3; grade 4, 0). In descending order of frequency, adverse events affected the gastrointestinal system (n=14), hematologic system (n=6), pulmonary system (n=2), and genito-urinary system (n=1). The adverse events did not affect adjuvant systemic chemotherapy schedules. One patient experienced disease recurrence in the liver 16 months after surgery. The remaining 9 patients have been well controlled by chemotherapy and/or observation during the follow-up period of 4 to 39 months after surgery. CONCLUSION: Intraoperative IP chemotherapy with cisplatin during surgical procedures is considered feasible for the treatment of primary epithelial ovarian cancer. Further studies, including long-term, prospective and comparative trials, are needed to validate the efficacy of this combined therapy. |
format | Online Article Text |
id | pubmed-3325355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Korean Society of Gynecologic Oncology and Colposcopy |
record_format | MEDLINE/PubMed |
spelling | pubmed-33253552012-04-20 Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer Kim, Myung Joo Jung, Yong Wook Seong, Seok Ju Yoon, Bo Sung Kim, Mi La Joo, Won Deok Song, Tae Jong J Gynecol Oncol Original Article OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers between April 2008 and February 2011. Cisplatin (70 mg/m(2) in 1 L normal saline solution) was administered in the abdominal cavity for 24 hours postoperatively and then adjuvant chemotherapy was started 2-4 weeks after surgery. Perioperative toxicity of the combined treatment was evaluated until the initiation of postoperative adjuvant chemotherapy. RESULTS: A total of 23 adverse events were observed in 9 of 10 patients (grade 1, 7; grade 2, 13; grade 3, 3; grade 4, 0). In descending order of frequency, adverse events affected the gastrointestinal system (n=14), hematologic system (n=6), pulmonary system (n=2), and genito-urinary system (n=1). The adverse events did not affect adjuvant systemic chemotherapy schedules. One patient experienced disease recurrence in the liver 16 months after surgery. The remaining 9 patients have been well controlled by chemotherapy and/or observation during the follow-up period of 4 to 39 months after surgery. CONCLUSION: Intraoperative IP chemotherapy with cisplatin during surgical procedures is considered feasible for the treatment of primary epithelial ovarian cancer. Further studies, including long-term, prospective and comparative trials, are needed to validate the efficacy of this combined therapy. Korean Society of Gynecologic Oncology and Colposcopy 2012-04 2012-04-03 /pmc/articles/PMC3325355/ /pubmed/22523624 http://dx.doi.org/10.3802/jgo.2012.23.2.91 Text en Copyright © 2012. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Myung Joo Jung, Yong Wook Seong, Seok Ju Yoon, Bo Sung Kim, Mi La Joo, Won Deok Song, Tae Jong Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title_full | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title_fullStr | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title_full_unstemmed | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title_short | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
title_sort | intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325355/ https://www.ncbi.nlm.nih.gov/pubmed/22523624 http://dx.doi.org/10.3802/jgo.2012.23.2.91 |
work_keys_str_mv | AT kimmyungjoo intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT jungyongwook intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT seongseokju intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT yoonbosung intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT kimmila intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT joowondeok intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer AT songtaejong intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer |